| |
Natalizumab (N=197) |
Fingolimod (N=194) |
p-value |
Total |
| Women (n,%) |
134(68.0%) |
130(67.0%) |
0.831 |
67.50% |
| Age |
34.5 ± 9.39 |
38.9 ± 9.34 |
<0.001 |
36.7 ± 9.61 |
| Duration of disease |
9.0 ± 7.00 |
10.1 ± 7.32 |
0.121 |
9.6 ± 7.17 |
| EDSS in the year preceding treatment |
2.3 ± 0.95 |
2.5 ± 1.14 |
0.099 |
2.43 ± 1.05 |
| ARR in the year preceding treatment |
1.9 ± 0.72 |
1.1 ± 0.74 |
<0.001 |
1.5 ± 0.84 |
| Patients with MRI activity at baseline (n,%) |
190(96.4%) |
135(70.7%) |
<0.001 |
325(83.8%) |
|
